Genmab A/S filings document the company’s reporting as a foreign private issuer and its formal company announcements on antibody-medicine operations, financial results, governance and share capital. Recent Form 6-K reports include interim financial information, DARZALEX® royalty-related sales disclosures from Johnson & Johnson, pipeline commentary for EPKINLY®, Rina-S® and petosemtamab, and updates incorporated by reference into Form S-8 registration statements.
The filing record also documents Danish-market disclosure matters, including major shareholder notifications, managerial transactions in shares and linked securities, amendments to the articles of association, and registered share capital reductions. These filings provide the formal record for Genmab’s capital structure, ownership notifications, governance documents and recurring biotechnology business disclosures.
Genmab A/S ownership disclosure: two institutional investors filed an amended Schedule 13G/A reporting beneficial ownership positions in Genmab common stock. The filing shows 3,557,484 shares beneficially owned representing 5.5% of the class and identifies Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd as the reporting persons.
The filing breaks the holdings down by voting and dispositive power: Orbis holds 3,549,674 shares with sole voting and dispositive power, and Allan Gray Australia holds 7,810 shares with sole voting and dispositive power. The filing states the reporting persons are non-U.S. institutions functionally equivalent to an investment adviser and disclaims group beneficial ownership.
Genmab A/S will increase its share capital by 2,346 shares after employees exercised warrants, a very small change equal to about 0.004% of the company’s share capital.
The new shares were subscribed for cash at prices between DKK 1,147.50 and DKK 1,362.50 per share, generating approximately DKK 3.0 million in proceeds for Genmab. These are ordinary shares with standard rights, including dividends, from the date of subscription.
After the capital increase, Genmab’s total nominal share capital will be DKK 62,353,067, corresponding to 62,353,067 shares with one vote each. The new shares will be listed on Nasdaq Copenhagen once the increase is registered with the Danish Business Authority.
Genmab A/S reports a change in a major shareholder’s position. Orbis Investment Management Limited informed Genmab that, as of May 8, 2026, it controlled voting rights attached to 3,166,357 Genmab shares, equal to 5.08% of the company’s share capital and voting rights.
A related Danish major holdings notification shows the Allan & Gill Gray Foundation group increasing its voting rights in Genmab to 5.0783%, up from 4.8471%, out of a total of 62,350,721 voting rights in the issuer. The filing also confirms there are no additional holdings via financial instruments.
Genmab A/S has completed a share capital reduction approved at its March 19, 2026 Annual General Meeting. The company cancelled 1,900,000 of its own shares, each with a nominal value of DKK 1, reducing the total nominal share capital by DKK 1,900,000.
After this reduction, Genmab’s total share capital is DKK 62,350,721, represented by 62,350,721 shares of DKK 1 each, corresponding to the same number of votes. The change has been registered with the Danish Business Authority and will be reflected in Nasdaq’s systems, which the company expects on April 21, 2026.
Genmab A/S reports a major shareholder update involving Orbis Investment Management Limited. As of April 13, 2026, Orbis controlled the voting rights to 3,114,318 Genmab shares, equal to 4.85% of the share capital and voting rights. This represents a small decrease from a previously reported level of about 5.01%. The notice is made under Section 30 of the Danish Capital Markets Act and confirms Orbis’ position as a significant, but minority, shareholder in Genmab.
Genmab A/S reports that worldwide net trade sales of DARZALEX (daratumumab), as reported by Johnson & Johnson, reached USD 3,964 million in the first quarter of 2026. Net trade sales were USD 2,208 million in the U.S. and USD 1,756 million in the rest of the world.
Genmab receives royalties on these global DARZALEX sales under its exclusive worldwide license agreement with Johnson & Johnson to develop, manufacture and commercialize daratumumab.
Genmab A/S filed a Form 6-K detailing routine equity compensation events for several senior leaders. On April 1, 2026, restricted stock units vested into Genmab shares for President & CEO Jan van de Winkel, CFO Anthony Pagano and four other executive vice presidents. Each transaction is reported as an acquisition of shares due to vesting of restricted stock units, conducted outside the market at a reference price of DKK 1,758.50 per share. The filing is also incorporated by reference into Genmab’s existing Form S-8 registration statements.